Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Oct;3(10):1108-12.
doi: 10.1158/2159-8290.CD-13-0219.

Connecting genomic alterations to cancer biology with proteomics: the NCI Clinical Proteomic Tumor Analysis Consortium

Matthew J Ellis  1 , Michael Gillette, Steven A Carr, Amanda G Paulovich, Richard D Smith, Karin K Rodland, R Reid Townsend, Christopher Kinsinger, Mehdi Mesri, Henry Rodriguez, Daniel C Liebler; Clinical Proteomic Tumor Analysis Consortium (CPTAC)
Affiliations

Connecting genomic alterations to cancer biology with proteomics: the NCI Clinical Proteomic Tumor Analysis Consortium

Matthew J Ellis et al. Cancer Discov. 2013 Oct.

Abstract

The National Cancer Institute (NCI) Clinical Proteomic Tumor Analysis Consortium is applying the latest generation of proteomic technologies to genomically annotated tumors from The Cancer Genome Atlas (TCGA) program, a joint initiative of the NCI and the National Human Genome Research Institute. By providing a fully integrated accounting of DNA, RNA, and protein abnormalities in individual tumors, these datasets will illuminate the complex relationship between genomic abnormalities and cancer phenotypes, thus producing biologic insights as well as a wave of novel candidate biomarkers and therapeutic targets amenable to verification using targeted mass spectrometry methods.

PubMed Disclaimer

Conflict of interest statement

The authors report no relevant conflicts of interest.

Figures

Figure 1
Figure 1
Proteogenomic integrated work flow for the Clinical Proteomic Tumor Analysis Consortium.
See this image and copyright information in PMC

References

    1. Ellis MJ, Perou CM. The genomic landscape of breast cancer as a therapeutic roadmap. Cancer Discov. 2013;3:27–34. - PMC - PubMed
    1. Goldstein TC, Paull EO, Ellis MJ, Stuart JM. Molecular pathways: extracting medical knowledge from high-throughput genomic data. Clinical cancer: an official journal of the American Association for Cancer Research. 2013;19:3114–20. - PMC - PubMed
    1. Picotti P, Aebersold R. Selected reaction monitoring-based proteomics: workflows, potential, pitfalls and future directions. Nature methods. 2012;9:555–66. - PubMed
    1. Gillette MA, Carr SA. Quantitative analysis of peptides and proteins in biomedicine by targeted mass spectrometry. Nature methods. 2013;10:28–34. - PMC - PubMed
    1. Breast Comprehensive molecular portraits of human breast tumours. Nature. 2012;490:61–70. - PMC - PubMed

Publication types

MeSH terms

Substances